{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T09:16:14Z","timestamp":1780478174965,"version":"3.54.1"},"reference-count":49,"publisher":"Bentham Science Publishers Ltd.","issue":"1","license":[{"start":{"date-parts":[[2010,4,28]],"date-time":"2010-04-28T00:00:00Z","timestamp":1272412800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":["opencardiovascularmedicinejournal.com","benthamopen.com"],"crossmark-restriction":true},"short-container-title":["TOCMJ"],"published-print":{"date-parts":[[2010,4,28]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p>Most patients with primary biliary cirrhosis (PBC) are treated with ursodeoxycholic acid (UDCA); however, some do not respond fully. PBC is also associated with dyslipidemia, but a link with vascular risk has not been confirmed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods and Results:<\/jats:title><jats:p>In this study we compared UDCA monotherapy with fenofibrate plus UDCA in PBC patients with incomplete biochemical response to UDCA monotherapy for \u2265 8 months. Ten patients (57.2\u00b113.3 years old) with PBC and persistent elevations of liver enzymes after treatment with UDCA (600 mg\/day) were randomized to continue UDCA (4 patients) or to receive micronized fenofibrate (200 mg\/day) plus UDCA (6 patients) for 8 weeks. Significant reductions in total cholesterol, triglycerides and non-high density lipoprotein cholesterol were observed in the combination treatment group. The serum activities of alkaline phosphatase, gamma-glutamyl transpeptidase and alanine aminotranferase also decreased in this group compared with baseline (-32.6%; p=0.012, -44%; p=0.031 and -16.9%; p=0.029, respectively). In contrast, no significant alterations in liver enzymes or lipid profile were observed in patients who continued UDCA monotherapy. The changes in the lipid and enzyme variables differed significantly (p&lt;0.03) between the 2 groups. Fenofibrate was well tolerated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions:<\/jats:title><jats:p>The administration of fenofibrate plus UDCA seems to be safe and may improve lipid and liver indices in patients with PBC who do not respond fully to UDCA monotherapy. Whether the improved lipid profile translates into a decreased risk of vascular events remains to be established.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1874192401004010120","type":"journal-article","created":{"date-parts":[[2010,5,25]],"date-time":"2010-05-25T13:18:29Z","timestamp":1274793509000},"page":"120-126","update-policy":"https:\/\/doi.org\/10.2174\/crossmark_policy","source":"Crossref","is-referenced-by-count":66,"title":["Fenofibrate in Primary Biliary Cirrhosis: A Pilot Study"],"prefix":"10.2174","volume":"4","author":[{"given":"E.N","family":"Liberopoulos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Florentin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.S","family":"Elisaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.P","family":"Mikhailidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Tsianos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"refR1","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1056\/NEJM199611213352107","volume":"335","author":"Kaplan MM","year":"1996","unstructured":"Kaplan MM. Primary biliary cirrhosis N Engl J Med 1996; 335 : 1570-80.","journal-title":"N Engl J Med"},{"key":"refR2","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/S0140-6736(87)91610-2","volume":"1","author":"Poupon R","year":"1987","unstructured":"Poupon R, Chretien Y, Poupon RE, Ballet F, Calmus Y, Darnis F. Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis? Lancet 1987; 1 : 834-6.","journal-title":"Lancet"},{"key":"refR3","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/S0140-6736(98)11293-X","volume":"354","author":"Goulis J","year":"1999","unstructured":"Goulis J, Leandro G, Burroughs AK. Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis Lancet 1999; 354 : 1053-60.","journal-title":"Lancet"},{"key":"refR4","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s00535-002-1102-7","volume":"38","author":"Kanda T","year":"2003","unstructured":"Kanda T, Yokosuka O, Imazeki F, Saisho H. Bezafibrate treatment a new medical approach for PBC patients? J Gastroenterol 2003; 38 : 573-8.","journal-title":"J Gastroenterol"},{"key":"refR5","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/j.1572-0241.2002.05413.x","volume":"97","author":"Kurihara T","year":"2002","unstructured":"Kurihara T, Maeda A, Shigemoto M, Yamashita K, Hashimoto E. Investigation into the efficacy of bezafibrate against primary biliary cirrhosis, with histological references from cases receiving long term monotherapy Am J Gastroenterol 2002; 97 : 212-4.","journal-title":"Am J Gastroenterol"},{"key":"refR6","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1111\/j.1572-0241.2000.03220.x","volume":"95","author":"Kurihara T","year":"2000","unstructured":"Kurihara T, Niimi A, Maeda A, Shigemoto M, Yamashita K. Bezafibrate in the treatment of primary biliary cirrhosis: comparison with ursodeoxycholic acid Am J Gastroenterol 2000; 95 : 2990-.","journal-title":"Am J Gastroenterol"},{"key":"refR7","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1572-0241.2000.01667.x","volume":"95","author":"Nakai S","year":"2000","unstructured":"Nakai S, Masaki T, Kurokohchi K, Deguchi A, Nishioka M. Combination therapy of bezafibrate and ursodeoxycholic acid in primary biliary cirrhosis: a preliminary study Am J Gastroenterol 2000; 95 : 326-7.","journal-title":"Am J Gastroenterol"},{"key":"refR8","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1034\/j.1600-0676.2001.021003223.x","volume":"21","author":"Ohmoto K","year":"2001","unstructured":"Ohmoto K, Mitsui Y, Yamamoto S. Effect of bezafibrate in primary biliary cirrhosis: a pilot study Liver 2001; 21 : 223-4.","journal-title":"Liver"},{"key":"refR9","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1007\/s00535-006-1778-1","volume":"41","author":"Ohmoto K","year":"2006","unstructured":"Ohmoto K, Yoshioka N, Yamamoto S. Long-term effect of bezafibrate on parameters of hepatic fibrosis in primary biliary cirrhosis J Gastroenterol 2006; 41 : 502-3.","journal-title":"J Gastroenterol"},{"key":"refR10","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1111\/j.1572-0241.2002.05645.x","volume":"97","author":"Yano K","year":"2002","unstructured":"Yano K, Kato H, Morita S, Takahara O, Ishibashi H, Furukawa R. Is bezafibrate histologically effective for primary biliary cirrhosis? Am J Gastroenterol 2002; 97 : 1075-7.","journal-title":"Am J Gastroenterol"},{"key":"refR11","first-page":"1518","volume":"47","author":"Miyaguchi S","year":"2000","unstructured":"Miyaguchi S, Ebinuma H, Imaeda H, et al. A novel treatment for refractory primary biliary cirrhosis? Hepatogastroenterology 2000; 47 : 1518-21.","journal-title":"Hepatogastroenterology"},{"key":"refR12","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1136\/gut.51.2.265","volume":"51","author":"Longo M","year":"2002","unstructured":"Longo M, Crosignani A, Battezzati PM, et al. Hyperlipidaemic state and cardiovascular risk in primary biliary cirrhosis Gut 2002; 51 : 265-9.","journal-title":"Gut"},{"key":"refR13","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1161\/01.RES.0000037427.73184.C1","volume":"91","author":"Kusuoka H","year":"2002","unstructured":"Kusuoka H, Hoffman JI. Advice on statistical analysis for circulation research Circ Res 2002; 91 : 662-71.","journal-title":"Circ Res"},{"key":"refR14","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1007\/s00535-006-1831-0","volume":"41","author":"Kita R","year":"2006","unstructured":"Kita R, Takamatsu S, Kimura T, Kokuryu H, Osaki Y, Tomono N. Bezafibrate may attenuate biliary damage associated with chronic liver diseases accompanied by high serum biliary enzyme levels J Gastroenterol 2006; 41 : 686-92.","journal-title":"J Gastroenterol"},{"key":"refR15","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/j.1872-034X.2007.00305.x","volume":"38","author":"Iwasaki S","year":"2008","unstructured":"Iwasaki S, Ohira H, Nishiguchi S, et al. The efficacy of ursodeoxycholic acid and bezafibrate combination therapy for primary biliary cirrhosis: A prospective, multicenter study Hepatol Res 2008; 38 : 557-64.","journal-title":"Hepatol Res"},{"key":"refR16","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1007\/s00535-004-1583-7","volume":"40","author":"Nakamuta M","year":"2005","unstructured":"Nakamuta M, Enjoji M, Kotoh K, Shimohashi N, Tanabe Y. Long-term fibrate treatment for PBC J Gastroenterol 2005; 40 : 546-7.","journal-title":"J Gastroenterol"},{"key":"refR17","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1021\/jm990554g","volume":"43","author":"Willson TM","year":"2000","unstructured":"Willson TM, Brown PJ, Sternbach DD, Henke BR. The PPARs: from orphan receptors to drug discovery J Med Chem 2000; 43 : 527-0.","journal-title":"J Med Chem"},{"key":"refR18","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1185\/030079900542786","volume":"16","author":"Milionis HJ","year":"2000","unstructured":"Milionis HJ, Elisaf MS, Mikhailidis DP. Treatment of dyslipidaemias in patients with established vascular disease: a revival of the fibrates Curr Med Res Opin 2000; 16 : 21-32.","journal-title":"Curr Med Res Opin"},{"key":"refR19","first-page":"165","volume":"2","author":"Feussner G","year":"1997","unstructured":"Feussner G, Kurth B, Lohrmann J. Comparative effects of bezafibrate and micronised fenofibrate in patients with type III hyperlipoproteinemia Eur J Med Res 1997; 2 : 165-8.","journal-title":"Eur J Med Res"},{"key":"refR20","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1111\/j.1572-0241.2002.05944.x","volume":"97","author":"Ohira H","year":"2002","unstructured":"Ohira H, Sato Y, Ueno T, Sata M. Fenofibrate treatment in patients with primary biliary cirrhosis Am J Gastroenterol 2002; 97 : 2147-9.","journal-title":"Am J Gastroenterol"},{"key":"refR21","doi-asserted-by":"crossref","first-page":"894","DOI":"10.3748\/wjg.v10.i6.894","volume":"10","author":"Dohmen K","year":"2004","unstructured":"Dohmen K, Mizuta T, Nakamuta M, Shimohashi N, Ishibashi H, Yamamoto K. Fenofibrate for patients with asymptomatic primary biliary cirrhosis World J Gastroenterol 2004; 10 : 894-.","journal-title":"World J Gastroenterol"},{"key":"refR22","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/hep.22670","volume":"49","author":"Walker LJ","year":"2009","unstructured":"Walker LJ, Newton J, Jones DE, Bassendine MF. Comment on biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis Hepatology 2009; 49 : 337-8.","journal-title":"Hepatology"},{"key":"refR23","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/384039a0","volume":"384","author":"Devchand PR","year":"1996","unstructured":"Devchand PR, Kelle H, Peters JM, Vazquez M, Gonzalez FJ, Wahli W. The PPARalpha-leukotriene B4 pathway to inflammation control Nature 1996; 384 : 39-43.","journal-title":"Nature"},{"key":"refR24","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/31701","volume":"393","author":"Staels B","year":"1998","unstructured":"Staels B, Koenig W, Habib A, et al. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPAR-gamma activators Nature 1998; 393 : 790-3.","journal-title":"Nature"},{"key":"refR25","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1006\/bbrc.1997.7236","volume":"238","author":"Calabresi L","year":"1997","unstructured":"Calabresi L, Franceschini G, Sirtori CR, et al. Inhibition of VCAM-1 expression in endothelial cells by reconstituted high density lipoproteins Biochem Biophys Res Commun 1997; 238 : 61-5.","journal-title":"Biochem Biophys Res Commun"},{"key":"refR26","first-page":"836","volume":"55","author":"Gulubova M","year":"2008","unstructured":"Gulubova M, Vlaykova T, Manolova I, Hadjipetkov P, Popharitov A. Implication of adhesion molecules in inflammation of the common bile duct in patients with secondary cholangitis due to biliary obstruction Hepatogastroenterology 2008; 55 : 836-41.","journal-title":"Hepatogastroenterology"},{"key":"refR27","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1042\/bj3140781","volume":"314","author":"Chianale J","year":"1996","unstructured":"Chianale J, Vollrath V, Wielandt AM, et al. Fibrates induce mdr2 gene expression and biliary phospholipid secretion in the mouse Biochem J 1996; 314 (Pt 3) : 781-6.","journal-title":"Biochem J"},{"key":"refR28","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/0092-8674(93)90380-9","volume":"75","author":"Smit JJ","year":"1993","unstructured":"Smit JJ, Schinkel AH, Oude Elferink RP, et al. Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease Cell 1993; 75 : 451-62.","journal-title":"Cell"},{"key":"refR29","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1006\/bbrc.2001.5893","volume":"288","author":"Hirano F","year":"2001","unstructured":"Hirano F, Kobayashi A, Hirano Y, Nomura Y, Fukawa E, Makino I. Bile acids regulate RANTES gene expression through its cognate NF-kappaB binding sites Biochem Biophys Res Commun 2001; 288 : 1095-1.","journal-title":"Biochem Biophys Res Commun"},{"key":"refR30","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S1567-5769(02)00275-8","volume":"3","author":"Hirano F","year":"2003","unstructured":"Hirano F, Kobayashi A, Makino I. Inhibition of TNF-alpha-induced RANTES expression in human hepatocyte-derived cells by fibrates the hypolipidemic drugs Int Immunopharmacol 2003; 3 : 225-32.","journal-title":"Int Immunopharmacol"},{"key":"refR31","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0014-2999(02)01902-7","volume":"448","author":"Hirano Y","year":"2002","unstructured":"Hirano Y, Hirano F, Fujii H, Makino I. Fibrates suppress chenodeoxycholic acid-induced RANTES expression through inhibition of NF-kappaB activation Eur J Pharmacol 2002; 448 : 19-26.","journal-title":"Eur J Pharmacol"},{"key":"refR32","doi-asserted-by":"crossref","first-page":"574","DOI":"10.2174\/138161208783885362","volume":"14","author":"Florentin M","year":"2008","unstructured":"Florentin M, Liberopoulos EN, Mikhailidis DP, Elisaf MS. Fibrate-associated adverse effects beyond muscle and liver toxicity Curr Pharm Des 2008; 14 : 574-87.","journal-title":"Curr Pharm Des"},{"key":"refR33","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1111\/j.1572-0241.2008.02092.x","volume":"103","author":"Solaymani-Dodaran M","year":"2008","unstructured":"Solaymani-Dodaran M, Aithal GP, Card T, West J. Risk of cardiovascular and cerebrovascular events in primary biliary cirrhosis: a population-based cohort study Am J Gastroenterol 2008; 103 : 2784-8.","journal-title":"Am J Gastroenterol"},{"key":"refR34","first-page":"415","volume":"138","author":"Balmer ML","year":"2008","unstructured":"Balmer ML, Dufour JF. Treatment of hypercholesterolemia in patients with primary biliary cirrhosis might be more beneficial than indicated Swiss Med Wkly 2008; 138 : 415-9.","journal-title":"Swiss Med Wkly"},{"key":"refR35","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s11938-001-0022-6","volume":"4","author":"Longo M","year":"2001","unstructured":"Longo M, Crosignani A, Podda M. Hyperlipidemia in Chronic Cholestatic Liver Disease Curr Treat Options Gastroenterol 2001; 4 : 111-4.","journal-title":"Curr Treat Options Gastroenterol"},{"key":"refR36","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0022-2275(20)31668-0","volume":"42","author":"Del Puppo M","year":"2001","unstructured":"Del Puppo M, Galli Kienle M, Crosignani A, et al. Cholesterol metabolism in primary biliary cirrhosis during simvastatin and UDCA administration J Lipid Res 2001; 42 : 437-1.","journal-title":"J Lipid Res"},{"key":"refR37","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/S0168-8278(02)00006-5","volume":"36","author":"Ritzel U","year":"2002","unstructured":"Ritzel U, Leonhardt U, Nather M, Schafer G, Armstrong VW, Ramadori G. Simvastatin in primary biliary cirrhosis: effects on serum lipids and distinct disease markers J Hepatol 2002; 36 : 454-8.","journal-title":"J Hepatol"},{"key":"refR38","author":"Stojakovic T","year":"2009","unstructured":"Stojakovic T, Claudel T, Putz-Bankuti C, et al. Low-dose atorvastatin improves dyslipidemia and vascular function in patients with primary biliary cirrhosis after one year of treatment Atherosclerosis 2009 sep 6; [Epub ahead of print]","journal-title":"Atherosclerosis"},{"key":"refR39","author":"Rajab MA","year":"2009","unstructured":"Rajab MA, Kaplan MM. Statins in Primary Biliary Cirrhosis: Are They Safe? Dig Dis Sci 2009 Oct 1; [Epub ahead of print]","journal-title":"Dig Dis Sci"},{"key":"refR40","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1002\/hep.21848","volume":"46","author":"Lewis JH","year":"2007","unstructured":"Lewis JH, Mortensen ME, Zweig S, Fusco MJ, Medoff JR, Belder R. Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial Hepatology 2007; 46 : 1453-63.","journal-title":"Hepatology"},{"key":"refR41","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1002\/hep.21741","volume":"46","author":"Stojakovic T","year":"2007","unstructured":"Stojakovic T, Putz-Bankuti C, Fauler G, et al. Atorvastatin in patients with primary biliary cirrhosis and incomplete biochemical response to ursodeoxycholic acid Hepatology 2007; 46 : 776-84.","journal-title":"Hepatology"},{"key":"refR42","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","volume":"366","author":"Keech A","year":"2005","unstructured":"Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial Lancet 2005; 366 : 1849-61.","journal-title":"Lancet"},{"key":"refR43","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1185\/030079906X104696","volume":"22","author":"Athyros VG","year":"2006","unstructured":"Athyros VG, Mikhailidis DP, Didangelos TP, et al. Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study Curr Med Res Opin 2006; 22 : 873-3.","journal-title":"Curr Med Res Opin"},{"key":"refR44","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1161\/ATVBAHA.108.170597","volume":"28","author":"Strasak AM","year":"2008","unstructured":"Strasak AM, Kelleher CC, Klenk J, et al. Longitudinal change in serum gamma-glutamyltransferase and cardiovascular disease mortality: a prospective population-based study in 76113 Austrian adults Arterioscler Thromb Vasc Biol 2008; 28 : 1857-65.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"refR45","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1161\/CIRCULATIONAHA.105.552547","volume":"112","author":"Ruttmann E","year":"2005","unstructured":"Ruttmann E, Brant LJ, Concin H, Diem G, Rapp K, Ulmer H. Gamma-glutamyltransferase as a risk factor for cardiovascular disease mortality an epidemiological investigation in a cohort of 163944 Austrian adults Circulation 2005; 112 : 2130-7.","journal-title":"Circulation"},{"key":"refR46","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1093\/eurheartj\/ehl086","volume":"27","author":"Lee DH","year":"2006","unstructured":"Lee DH, Silventoinen K, Hu G, et al. Serum gamma-glutamyltransferase predicts non-fatal myocardial infarction and fatal coronary heart disease among 28838 middle-aged men and women Eur Heart J 2006; 27 : 2170-6.","journal-title":"Eur Heart J"},{"key":"refR47","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.atherosclerosis.2008.01.019","volume":"201","author":"Wannamethee SG","year":"2008","unstructured":"Wannamethee SG, Lennon L, Shaper AG. The value of gamma-glutamyltransferase in cardiovascular risk prediction in men without diagnosed cardiovascular disease or diabetes Atherosclerosis 2008; 201 : 168-75.","journal-title":"Atherosclerosis"},{"key":"refR48","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.arcmed.2009.07.012","volume":"40","author":"Korantzopoulos P","year":"2009","unstructured":"Korantzopoulos P, Tzimas P, Kalantzi K. Association between serum gamma-glutamyltransferase and acute ischemic nonembolic stroke in elderly subjects Arch Med Res 2009; 40 : 582-9.","journal-title":"Arch Med Res"},{"key":"refR49","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.cca.2007.06.005","volume":"384","author":"Lippi G","year":"2007","unstructured":"Lippi G, Targher G, Montagnana M, Salvagno GL, Guidi GC. Relationship between gamma-glutamyltransferase lipids and lipoprotein(a) in the general population Clin Chim Acta 2007; 384 : 163-6.","journal-title":"Clin Chim Acta"}],"container-title":["The Open Cardiovascular Medicine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/opencardiovascularmedicinejournal.com\/contents\/volumes\/V4\/TOCMJ-4-120\/TOCMJ-4-120.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/opencardiovascularmedicinejournal.com\/contents\/volumes\/V4\/TOCMJ-4-120\/TOCMJ-4-120.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/opencardiovascularmedicinejournal.com\/contents\/volumes\/V4\/TOCMJ-4-120\/TOCMJ-4-120.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T05:39:36Z","timestamp":1635399576000},"score":1,"resource":{"primary":{"URL":"https:\/\/opencardiovascularmedicinejournal.com\/VOLUME\/4\/PAGE\/120\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4,28]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,4,28]]}},"alternative-id":["TOCMJ-4-120"],"URL":"https:\/\/doi.org\/10.2174\/1874192401004010120","relation":{},"ISSN":["1874-1924"],"issn-type":[{"value":"1874-1924","type":"print"}],"subject":[],"published":{"date-parts":[[2010,4,28]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2010-3-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2010-3-31","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2010-4-2","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2010-4-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}